Rising interest in personalized therapies drives market growth in cell and gene therapy.
- Market valued at USD 146.2 billion by 2032
- Fueled by demand for personalized therapies
- Growth in viral vector capacity and bioprocessing
The cell and gene therapy manufacturing market is projected to grow significantly, reaching USD 146.2 billion by 2032. This rise is largely driven by the increasing need for personalized therapies that cater to individual patient needs. Strong advancements in technology, particularly in viral vector capacity, are also contributing to this surge in demand.
The market's growth can be attributed to innovations in automated bioprocessing and a broader acceptance of gene therapies. As companies expand their capabilities and improve production efficiencies, the overall landscape of cell and gene therapy manufacturing is evolving. This shift is expected to enhance the availability of cutting-edge treatments, ushering in a new era of personalized medical care.
With the ongoing evolution in manufacturing processes, stakeholders in the pharmaceutical industry are paying close attention to developments in this sector. The emphasis on personalized therapies points to a promising future for both patients and manufacturers in the cell and gene therapy landscape.
